These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study. Buhl L; Thurau S; Kern C Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):1101-1108. PubMed ID: 36399176 [TBL] [Abstract][Full Text] [Related]
6. The 0.2-μg/day Fluocinolone Acetonide Intravitreal Implant in Chronic Noninfectious Posterior Uveitis: A 3-year Randomized Trial in India. Biswas J; Tyagi M; Agarwal M; Ophthalmol Sci; 2024; 4(1):100403. PubMed ID: 38027419 [TBL] [Abstract][Full Text] [Related]
7. Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant. Parekh A; Srivastava S; Bena J; Albini T; Nguyen QD; Goldstein DA JAMA Ophthalmol; 2015 May; 133(5):568-73. PubMed ID: 25719937 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal Fluocinolone 0.19mg Implant in the Management of Chronic Non-Infectious Uveitis: 12-Month Outcomes from a Single Tertiary Centre. Pockar S; Leal I; Chhabra R; Jones NP; Steeples LR Ocul Immunol Inflamm; 2023 Oct; 31(8):1572-1578. PubMed ID: 34124978 [TBL] [Abstract][Full Text] [Related]
9. Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant. Cai CX; Skalak C; Keenan RT; Grewal DS; Jaffe GJ Graefes Arch Clin Exp Ophthalmol; 2020 May; 258(5):1023-1030. PubMed ID: 32114654 [TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758 [TBL] [Abstract][Full Text] [Related]
11. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma. Malone PE; Herndon LW; Muir KW; Jaffe GJ Am J Ophthalmol; 2010 May; 149(5):800-6.e1. PubMed ID: 20189158 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Clinical Outcomes of the 0.18 Mg Fluocinolone Acetonide Intravitreal Implant Following Local Corticosteroid Burst in Noninfectious Uveitis. Janetos TM; Koreishi A; Goldstein DA Ocul Immunol Inflamm; 2024 Jan; ():1-6. PubMed ID: 38194443 [TBL] [Abstract][Full Text] [Related]
13. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. Arcinue CA; Cerón OM; Foster CS J Ocul Pharmacol Ther; 2013 Jun; 29(5):501-7. PubMed ID: 23297752 [TBL] [Abstract][Full Text] [Related]
15. Intravitreal fluocinolone acetonide 0.19 mg (Iluvien®) for the treatment of uveitic macular edema: 2-year follow-up of 20 patients. Studsgaard A; Clemmensen KØ; Nielsen MS Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1633-1639. PubMed ID: 34851465 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of the Fluocinolone Acetonide (Yutiq) Intravitreal Implant as Monotherapy for Uveitis. Mahmud H; Ahmad TR; Gonzales JA; Stewart JM Ocul Immunol Inflamm; 2023 Oct; 31(8):1603-1607. PubMed ID: 35793136 [TBL] [Abstract][Full Text] [Related]